Vaccine-led recovery should support RDI's increasingly focused portfolio. Starwood sees value in RDI turnaround. LONG at levels around the offer price (121.35p), on expectations of a sweetened offer.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.